PPARγ ligands induce growth inhibition and apoptosis through p63 and p73 in human ovarian cancer cells

Biochemical and Biophysical Research Communications

Volumn 406, Issue 3, 2011, Pages 389-395

  Kim, Soyeon ^a   Lee, Jae Jung ^a   Heo, Dae Seog ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Cell death; Ovarian cancer cells; P63; P73; PPAR ligands

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CASPASE 3; CIGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEIN BAX; PROTEIN P21; PROTEIN P63; PROTEIN P73; SHORT HAIRPIN RNA; TROGLITAZONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; DOSE RESPONSE; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PPAR GAMMA; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

EID: 79952739732     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.02.052     Document Type: Article

References (30)

1. Baba T., Kariya M., Higuchi T., Mandai M., Matsumura N., Kondoh E., Miyanishi M., Fukuhara K., Takakura K., Fujii S. Neuropilin-1 promotes unlimited growth of ovarian cancer by evading contact inhibition. Gynecol. Oncol. 2007, 105(3):703-711.
2. Kersten S., Desvergne B., Wahli W. Roles of PPARs in health and disease. Nature 2000, 405:421-424.
3. Burton J.D., Goldenberg D.M., Blumenthal R.D. Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types. PPAR Res. 2008, 2008:494161.
4. Grommes C., Landreth G.E., Heneka M.T. Antineoplastic effects of peroxisome proliferatoractivated receptor [gamma] agonists. Lancet Oncol. 2004, 5:419-429.
5. Lyles B.E., Akinyeke T.O., Moss P.E., Stewart L.V. Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways. Cell Cycle 2009, 8:268-277.
6. Shim J., Kim B.H., Kim Y.I., Kim K.Y., Hwangbo Y., Jang J.Y., Dong S.H., Kim H.J., Chang Y.W., Chang R. The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells. Int. J. Oncol. 2010, 36:223-231.
7. Dong Y.W., Wang X.P., Wu K. Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition. World J. Gastroenterol. 2009, 15:441-448.
8. Shiau C.W., Yang C.C., Kulp S.K., Chen K.F., Chen C.S., Huang J.W., Chen C.S. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res. 2005, 65:1561-1569.
9. Han S., Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol. Cancer Ther. 2006, 5:430-437.
10. Inamoto T., Shah J.B., Kamat A.M. Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer. Urol. Oncol. 2009, 27:585-591.
11. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408:307-310.
12. M.P. Deyoung, L.W. Ellisen, p63 and p73 in human cancer: defining the network, Oncogene (2007).
13. Nagamine M., Okumura T., Tanno S., Sawamukai M., Motomura W., Takahashi N., Kohgo Y. PPAR gamma ligand-induced apoptosis through a p53-dependent mechanism in human gastric cancer cells. Cancer Sci. 2003, 94:338-343.
14. Elstner E., Williamson E.A., Zang C., Fritz J., Heber D., Fenner M., Possinger K., Koeffler H.P. Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res. Treat. 2002, 74:155-165.
15. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.C., Valent A., Minty A., Chalon P., Lelias J.M., Dumont X., Ferrara P., McKeon F., Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997, 90:809-819.
16. Pietsch E.C., Sykes S.M., McMahon S.B., Murphy M.E. The p53 family and programmed cell death. Oncogene 2008, 27:6507-6521.
17. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dotsch V., Andrews N.C., Caput D., McKeon F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 1998, 2:305-316.
18. Lee J.J., Kim S., Yeom Y.I., Heo D.S. Enhanced specificity of the p53 family proteins-based adenoviral gene therapy in uterine cervical cancer cells with E2F1-responsive promoters. Cancer Biol. Ther. 2006, 5:1502-1510.
19. Han S., Sidell N., Fisher P.B., Roman J. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells. Clin. Cancer Res. 2004, 10:1911-1919.
20. Lei P., Abdelrahim M., Safe S. 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes inhibit ovarian cancer cell growth through peroxisome proliferator-activated receptor-dependent and independent pathways. Mol. Cancer Ther. 2006, 5:2324-2336.
21. Han C., Demetris A.J., Michalopoulos G.K., Zhan Q., Shelhamer J.H., Wu T. PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway. Hepatology 2003, 38:167-177.
22. Vignati S., Albertini V., Rinaldi A., Kwee I., Riva C., Oldrini R., Capella C., Bertoni F., Carbone G.M., Catapano C.V. Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Neoplasia 2006, 8:851-861.
23. Brown C.J., Lain S., Verma C.S., Fersht A.R., Lane D.P. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 2009, 9:862-873.
24. Haupt Y., Rowan S., Shaulian E., Kazaz A., Vousden K., Oren M. p53 mediated apoptosis in HeLa cells: transcription dependent and independent mechanisms. Leukemia 1997, 11(Suppl. 3):337-339.
25. Levrero M., De Laurenzi V., Costanzo A., Gong J., Wang J.Y., Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J. Cell Sci. 2000, 113(Pt 10):1661-1670.
26. Collavin L., Lunardi A., Del Sal G. p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ. 2010, 17:901-911.
27. Lin K.W., Nam S.Y., Toh W.H., Dulloo I., Sabapathy K. Multiple stress signals induce p73beta accumulation. Neoplasia 2004, 6:546-557.
28. Petitjean A., Ruptier C., Tribollet V., Hautefeuille A., Chardon F., Cavard C., Puisieux A., Hainaut P., Caron de Fromentel C. Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and cross talk with DeltaNp73. Carcinogenesis 2008, 29:273-281.
29. Goldschneider D., Blanc E., Raguenez G., Haddada H., Benard J., Douc-Rasy S. When p53 needs p73 to be functional - forced p73 expression induces nuclear accumulation of endogenous p53 protein. Cancer Lett. 2003, 197:99-103.
30. Johnson J., Lagowski J., Lawson S., Liu Y., Kulesz-Martin M. p73 expression modulates p63 and Mdm2 protein presence in complex with p53 family-specific DNA target sequence in squamous cell carcinogenesis. Oncogene 2008, 27:2780-2787.